discontinuing treatment and predicting relapse in cml
Published 6 years ago • 1.3K plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
6:35
measuring residual disease in granulocytes to predict relapse after therapy cessation in cml
-
2:18
recommendations for treatment discontinuation in cml
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
2:42
the use of targeted therapy to prevent relapse post-transplant
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
58:27
laboratory nonconformance (event) management
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:26
the current approaches to treating dlbcl in the frontline and relapsed settings
-
1:20
regulation of tetraspanin cd63 in cml progression: single-cell analysis of asymmetric hsc division
-
2:18
the current landscape of treatment for bpdcn
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
2:12
the impact of setd2 loss on cml progression
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:31
cll: relapsed disease, discontinuation and mrd
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
0:52
the use of dli to prevent relapse
-
2:46
optimizing preceding and consolidation therapies to prevent post-car-t relapse in b-all
-
3:10
the potential for early identification of relapse in dlbcl using serial ctdna sampling
-
1:27
factors to consider in frontline and relapsed cll before treatment
-
2:06
managing relapsed all: the role of novel cellular therapies & importance of conditioning regimens